The tweet was deleted by the author.
But we saved everything 🙂.
Definium Therapeutics presented new developments in artificial intelligence applications for psychiatric drug development at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach.
The company’s Chief Medical Officer joined leading industry experts to discuss how AI is influencing the future of mental health care. The event signaled growing momentum behind digital tools shaping the next generation of psychiatric treatments. Details on specific solutions are pending further disclosure.
Definium Therapeutics previously started patient dosing in Ascend, its second Phase 3 pivotal study for major depressive disorder, according to company disclosures. The firm also revealed pre-clinical safety results for its psychedelic therapy at the APA Annual Meeting earlier this year. These updates come as the company expands its focus to AI-driven drug development.